- Home
- SILC vs GALT Comparison
SILC vs GALT Comparison
Compare SILC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- GALT
- Stock Information
- Founded
- SILC 1987
- GALT 2000
- Country
- SILC Israel
- GALT United States
- Employees
- SILC N/A
- GALT N/A
- Industry
- SILC Computer Manufacturing
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- GALT Health Care
- Exchange
- SILC Nasdaq
- GALT Nasdaq
- Market Cap
- SILC 86.2M
- GALT 83.5M
- IPO Year
- SILC 1994
- GALT N/A
- Fundamental
- Price
- SILC $15.27
- GALT $2.80
- Analyst Decision
- SILC Hold
- GALT Buy
- Analyst Count
- SILC 2
- GALT 2
- Target Price
- SILC N/A
- GALT $6.00
- AVG Volume (30 Days)
- SILC 12.6K
- GALT 1.5M
- Earning Date
- SILC 07-31-2025
- GALT 08-12-2025
- Dividend Yield
- SILC N/A
- GALT N/A
- EPS Growth
- SILC N/A
- GALT N/A
- EPS
- SILC N/A
- GALT N/A
- Revenue
- SILC $58,134,000.00
- GALT N/A
- Revenue This Year
- SILC $6.26
- GALT N/A
- Revenue Next Year
- SILC $19.14
- GALT N/A
- P/E Ratio
- SILC N/A
- GALT N/A
- Revenue Growth
- SILC N/A
- GALT N/A
- 52 Week Low
- SILC $11.35
- GALT $0.73
- 52 Week High
- SILC $18.24
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- SILC 50.22
- GALT 67.38
- Support Level
- SILC $14.93
- GALT $2.07
- Resistance Level
- SILC $15.93
- GALT $2.36
- Average True Range (ATR)
- SILC 0.55
- GALT 0.24
- MACD
- SILC -0.01
- GALT 0.03
- Stochastic Oscillator
- SILC 31.78
- GALT 81.11
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.